Tag: Rectal Cancer

Posted on

National Cancer Institute “Cancer Moonshot Biobank”

Dotted QR code with retro pixel dinosaur
NCT#:NCT04314401
NCT QR Code
Title:National Cancer Institute “Cancer Moonshot Biobank”
Protocol:Moonshot
Cancer Type: Multiple cancer types:
Colorectal cancer: Stage IV;
Non-small cell or small cell lung cancer: Stage III/IV;
Prostate cancer: metastatic prostate cancer;
Gastric cancer, NOS: Stage IV;
Esophageal cancer, NOS: Stage IV;
Adenocarcinoma of gastroesophageal junction: Stage IV;
High Grade Serous ovarian cancer: Stage III/IV;
Invasive breast carcinoma: Stage III/IV;
Melanoma: Stage III/IV;
Acute myeloid leukemia;
Multiple myeloma.
Study Sponsor: National Cancer Institute (NCI)
Brief Summary:  This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The “Cancer Moonshot Biobank” is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient’s cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.
Study Type: Observational
Date Opened at SVMHS:  January 24, 2025
Recruitment Status:  Recruiting
Study Population:   13 Years and older (Child,  Adult,  Older Adult)
Eligibility Criteria: Diagnosed with one of the following: Colorectal cancer: stage IV, Non-small cell or small cell lung cancer: stage III/IV, Prostate cancer: metastatic prostate cancer, Gastric cancer, not otherwise specified (NOS): stage IV, Esophageal cancer, NOS: stage IV, Adenocarcinoma of gastroesophageal junction: stage IV, High grade serous ovarian cancer: stage III/IV, Invasive breast carcinoma: stage III/IV, Melanoma: stage III/IV, Acute myeloid leukemia, Multiple myeloma
Principal Investigator:  Geetha N. Varma, MD, Oncology, Salinas Valley Health Cancer Care, (831) 755-1701
Participating Institution:  Salinas Valley Memorial Healthcare System & Salinas Valley Medical Clinics & Salinas Valley Memorial Hospital
SVMHS Clinical Research Program:  Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, tnielsen2@svmh.com
Link to ClinicalTrials.gov:  https://clinicaltrials.gov/study/NCT04314401?cond=moonshot&rank=1#study-overview
Posted on

A022104 – Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)

Dotted QR code with pixel dinosaur

NCT#:NCT05610163
NCT QR Code
Title:A022104 – Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (JANUS)
Protocol:A022104
Cancer Type: Rectal Cancer
Study Sponsor: Alliance/NCI
Brief Summary:  This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan ), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. FOLFOX or CAPOX are used after chemoradiation as usual treatment for rectal cancer. Giving FOLFIRINOX after chemoradiation may increase the response rate and lead to higher rates of clinical complete response (with a chance of avoiding surgery) compared to FOLFOX or CAPOX after chemoradiation in patients with locally advanced rectal cancer.
Study Type: Interventional
Date Opened at SVH:  February 15, 2022
Recruitment Status:  Closed
Study Population:  
Eligibility Criteria: See SCHEMA
Principal Investigator:  Geetha N. Varma, MD, Oncology, Salinas Valley Health Cancer Care, (831) 755-1701
Participating Institution:  Salinas Valley Health
Salinas Valley Health Clinical Research Program:  Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, research@salinasvalleyhealth.com
Link to ClinicalTrials.gov:  https://clinicaltrials.gov/ct2/show/record/NCT05610163?term=A022104&draw=2&rank=1
SchemaSchema